ceftazidime
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
3726
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
December 12, 2025
The promising activity of apple cider vinegar on MDR Klebsiella spp. (K. variicola and K. pneumoniae) emerging pathogens in chicken.
(PubMed, Vet Res Commun)
- "The Klebsiella isolates exhibited remarkable resistance against ampicillin (94.7%), cefotaxime (89.5%), and ceftazidime (86.9%). Our data indicated multiple health risks linked to phenotypic and genotypic resistance, as well as zoonotic importance. The Apple Cider Vinegar (ACV) possesses significant antibacterial properties."
Journal • Infectious Disease • Pneumonia
December 12, 2025
β-Lactam dosing in critically ill children: predictors for target non-attainment.
(PubMed, J Antimicrob Chemother)
- "This study found an eGFR ≥90 mL/min/1.73 m2 to be associated with target non-attainment, indicating that kidney function should be taken into account when identifying individuals who may require higher dosages. These results may help identify subpopulations of paediatric patients requiring higher dosages or continuous infusion in order to achieve adequate β-lactam exposure."
Journal • Pediatrics
December 12, 2025
Evaluation of resistance modulation in MDR Pseudomonas aeruginosa and Klebsiella pneumoniae using peppermint oil nanoemulsion: integrating antibacterial assays and molecular modeling.
(PubMed, Front Microbiol)
- "The bacterial isolates were resistant to Levofloxacin, Penicillin G, Ceftazidime, and amoxicillin-clavulanic acid (AMC). These results position PEONE as a promising, plant-based alternative for combating antibiotic-resistant urinary tract infections. Further in vivo studies are warranted to explore its clinical applicability and safety profile."
Journal • Infectious Disease • Nephrology • Pneumonia
December 12, 2025
Phage-mediated control of melioidosis in Southern China: molecular insights and therapeutic potential of N4-like viruses from Hainan.
(PubMed, BMC Microbiol)
- "As a continuation of our previous work, the identification of these phages addresses the natural occurrence of vB_BpP_HN01-insensitive strains and enhances understanding of B. pseudomallei phage diversity in Hainan. However, owing to close genetic similarity, cocktail formulation remains unfeasible, warranting further efforts to isolate more diverse novel phages."
Journal • Infectious Disease • Septic Shock
December 11, 2025
Genomic insights and molecular epidemiology through whole genome sequencing in clinical Serratia marcescens ST-367 isolated from the Kingdom of Bahrain.
(PubMed, J Infect Public Health)
- "To our knowledge, this is the first report of S. marcescens ST-367 in the Gulf Cooperation Council. The genetic diversity and mechanisms of virulence and antibiotic resistance in this isolate shed light on the evolution of high-risk isolates. Additionally, this will serve as a foundation for future extensively drug-resistant isolates."
Journal • Gene Therapies • Infectious Disease
December 10, 2025
Ceftazidime Combined with Bifico Improves Therapeutic Efficacy and Intestinal Safety in a Mouse Model of Pseudomonas aeruginosa Pneumonia.
(PubMed, Curr Microbiol)
- "Notably, Ceftazidime-induced gut dysbiosis was alleviated by Bifico, which mitigated intestinal inflammation and restored microbial diversity, as reflected by a Chao index comparable to control and higher than Ceftazidime alone (Ceftazidime-Bifico combination treatment: mean ± SD = 482.22 ± 73.21 vs. Ceftazidime treatment: mean ± SD = 349.64 ± 61.14, p < 0.05). These findings indicate that the Ceftazidime-Bifico combination enhances therapeutic efficacy while preserving gut homeostasis, representing a promising and safer strategy for managing bacterial pneumonia."
Journal • Preclinical • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Pneumonia • Respiratory Diseases
December 08, 2025
Strain-Specific Modulation of Biofilm and Motility in Pseudomonas aeruginosa by Danshen-Derived Compounds and Their Impact on Antibiotic Susceptibility.
(PubMed, J Appl Microbiol)
- "Danshen-derived diterpenoids exert strain-specific effects on P. aeruginosa biofilm formation and motility, and selectively potentiate ceftazidime activity against MDR isolates."
Journal
December 07, 2025
Antibiotic-Associated Encephalopathy Induced by Cefmetazole in a Hemodialysis Patient: Case Report.
(PubMed, J Infect Chemother)
- "While cefepime, ceftazidime, and ceftriaxone are well-documented causes, cefmetazole (CMZ) has not been widely recognized for neurotoxicity. A Naranjo score of 5 supported a diagnosis of CMZ-induced AAE. This case underscores the potential neurotoxicity of CMZ and emphasizes the importance of early recognition of AAE in patients with renal dysfunction."
Journal • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Epilepsy • Infectious Disease • Movement Disorders • Nephrology • Renal Disease
December 05, 2025
Revealing the most contaminated stages and spots of foodborne pathogens and antibiotic resistance along the whole fish production chain in Greek aquaculture.
(PubMed, Food Microbiol)
- "These potential pathogens, mainly isolated from surfaces and water of weaning and pre-fattening tanks, fish feeds, working surfaces, fish transport boxes, concrete floors and fish especially from transport boxes and harvesting, presented a noteworthy resistance to most antibiotics tested (e.g., Clindamycin, Nalidixic acid, Streptomycin, Sulphonamides, Ceftazidime, Erythromycin, Vancomycin, Penicillin G, and Cefoxitin). The findings underscore the importance of early detection and intervention strategies to mitigate ARB transmission, thereby enhancing the safety and quality of aquaculture products."
Journal • Infectious Disease • Pneumonia
December 04, 2025
Epidemiological cut-off values for Vibrio parahaemolyticus calculated from disc diffusion inhibition zone size data generated at 35 and 28°C.
(PubMed, Dis Aquat Organ)
- "Cut-off values calculated from data obtained at 35 and 28°C were ≥23 and ≥24 mm for ceftazidime, ≥18 and ≥20 mm for enrofloxacin, ≥28 and ≥29 mm for florfenicol, ≥14 and ≥14 mm for gentamicin, ≥29 and ≥32 mm for meropenem, ≥17 and ≥18 mm for oxolinic acid, ≥22 and ≥24 mm for oxytetracycline, as well as ≥19 and ≥21 mm for trimethoprim/sulfamethoxazole. The mean of the differences calculated for 1314 paired observations was 0.38 mm with a standard deviation of 2.68 mm. The data generated in this work will be submitted to the Clinical and Laboratory Standards Institute and the European Committee on Antimicrobial Susceptibility Testing for consideration in their setting of internationally agreed-upon epidemiological cut-off values for V. parahaemolyticus that are essential for interpreting antimicrobial susceptibility testing data of this species."
Journal
December 03, 2025
Evolution and high transferability of an IncN/FII plasmid harboring blaKPC-2/blaKPC-33 in Enterobacter intestinihominis under ceftazidime pressure.
(PubMed, BMC Microbiol)
- No abstract available
Journal
December 02, 2025
Pharmacokinetics, safety, and tolerability of nacubactam (OP0595) after intravenous infusion: a randomized, double-blind, placebo-controlled phase I clinical trial in healthy Chinese male subjects.
(PubMed, Clin Exp Med)
- P1 | "Nacubactam, a novel β-lactamase inhibitor, combined with cefepime or aztreonam, effectively supports CRE infection treatment...Its combination with ceftazidime or aztreonam is promising for treating multidrug-resistant Gram-negative bacterial infections...In this work, we conducted a phase I randomized, double-blind, placebo-controlled trial to clinically evaluate nacubactam for the first time in healthy Chinese male subjects, demonstrating its good safety profile, dose-proportional pharmacokinetics, and mainly renal excretion. These data provide insights into the clinical application of nacubactam.Trial registration This trial was registered on the Chinese Clinical Trial Registration website, registration number ChiCTR2500103582."
Clinical • Journal • P1 data • PK/PD data • Infectious Disease
November 23, 2025
Dreaded But Decipherable: Diffuse Alveolar Hemorrhage
(APSR 2025)
- "Case Report : A 20-year-old female, known case of Systemic Lupus Erythematosus, involving renal and hematologic systems, underwent Cyclophosphamide and Rituximab infusion...She was started on Meropenem and Vancomycin...Antibiotics were shifted to Ceftazidime and Vancomycin...Supportive blood transfusion with packed RBC and platelet concentrate and tranexamic acid were given...Treatment involves 3 major disciplines: Stabilization of Respiratory status, Treatment of Underlying disease, and Rapid and Effective local hemostasis. In this case, early recognition and aggressive immunosuppressive therapy led to favorable outcomes."
Cardiovascular • Hematological Disorders • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Pneumonia • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases • Rheumatology • Systemic Lupus Erythematosus • Thrombocytopenia
December 01, 2025
The impact of the COVID-19 pandemic on nosocomial infections and antimicrobial resistance (AMR) in intensive care units.
(PubMed, New Microbes New Infect)
- "Resistance to ceftazidime rose in P. aeruginosa (22.2 % vs. 56.3 %, p = 0.042), while methicillin resistance in Staphylococcus aureus declined (75.0 % vs. 25.0 %, p = 0.044)...While multidrug resistance remains a pressing concern, most changes were limited in scope. These findings provide locally relevant data that can inform infection control and AMR surveillance strategies in North African ICUs."
Journal • Critical care • Infectious Disease • Nephrology • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases
November 30, 2025
Antibiotic Resistance Genes in Klebsiella pneumoniae and Heavy Metal Contamination in Tilapia (Oreochromis niloticus): A Public Health Risk Assessment in Bangladesh.
(PubMed, Vet Med Sci)
- "The prevalence of K. pneumoniae and heavy metals in tilapia in this study should be a matter of concern to public health risk management."
Journal • Infectious Disease • Oncology • Pneumonia
November 30, 2025
Prevalence, Risk Factors, and Antimicrobial Susceptibility Patterns of Salmonella From Bulk Milk at the Dairy Farm Level in Mekelle and Southeast Zones of Tigrai, Ethiopia.
(PubMed, Microbiologyopen)
- "Five (83.3%) isolates of Salmonella showed resistance to ampicillin and tetracycline, and four (66.7%) to streptomycin. All Salmonella isolates were susceptible to ceftazidime and cefotaxime...Three Salmonella isolates showed resistance to four and six antimicrobial classes. The finding highlights the need for appropriate hygiene practices and the correct use of antibiotics in the farms."
Journal • Infectious Disease
November 30, 2025
Antimicrobial Resistance of Acinetobacter Species and Pseudomonas Species in a Tertiary Care Center in Gandaki Province, Nepal.
(PubMed, J Nepal Health Res Counc)
- "The study underscores alarming levels of antimicrobial resistance in Acinetobacter species and Pseudomonas species. Acinetobacter species demonstrated higher resistance to most antibiotics compared to Pseudomonas species. The variation in resistance patterns across sample types highlights the need of infection site and pathogen-specific antibiotic stewardship strategies."
Journal • Retrospective data • Infectious Disease
November 30, 2025
Carbapenemase Producing Multi Drug Resistant Klebsiella pneumoniae from a Referral Hospital in Nepal.
(PubMed, J Nepal Health Res Counc)
- "The study underscores alarming levels of antimicrobial resistance in Acinetobacter species and Pseudomonas species. Acinetobacter species demonstrated higher resistance to most antibiotics compared to Pseudomonas species. The variation in resistance patterns across sample types highlights the need of infection site and pathogen-specific antibiotic stewardship strategies."
Journal • Retrospective data • Infectious Disease • Pneumonia
November 29, 2025
Comparative pharmacokinetics of ceftazidime in Siamese crocodiles after intramuscular administration between forelimb and hindlimb.
(PubMed, Vet Res Commun)
- "Comparative analysis with other ectotherms revealed species-specific variation, highlighting the need for targeted dosing strategies. Further studies are warranted, involving repeated dosing and pharmacodynamic evaluation, to optimize CAZ use in crocodilian medicine."
Clinical • Journal • PK/PD data • Infectious Disease
November 25, 2025
Incidence and antimicrobial resistance of non-typhoidal Salmonella enterica in stool samples from children under five in peri-urban Ouagadougou, Burkina Faso.
(PubMed, BMC Microbiol)
- "This study demonstrates a substantial burden of NTS infections in children under five in peri-urban Burkina Faso. Although MDR prevalence was low, high tetracycline resistance indicates widespread circulation of resistant strains. Continuous AMR surveillance is essential to guide treatment and preserve antibiotic efficacy."
Journal • Infectious Disease
November 28, 2025
Proposal of metagenomic-origin LRA-5 as a precursor of active β-lactamases through Tyr69Gln and Val166Glu amino acid substitutions: a functional and structural analysis.
(PubMed, Antimicrob Agents Chemother)
- "Interactions observed between LRA-5 and ceftazidime (2.35 Å; PDB 8EO6) show structural conservation with other β-lactamases...Circular dichroism results confirm that amino acid substitutions in LRA-5 do not affect the overall content of the secondary/tertiary structures. Evidence suggests that alternative evolutionary paths could have occurred for β-lactamases like LRA-5, produced by environmental microorganisms: (i) proteins having similar structural features than active β-lactamases may accumulate a small number of mutations (e.g., Y69Q/V166E) to yield active enzymes and (ii) the β-lactamase fold may have lost key residues in the absence of antibiotics."
Journal
November 28, 2025
Regulatory relationships among aldB, ampH, and acoR and their impact on β-lactam susceptibility in Phytobacter diazotrophicus.
(PubMed, Front Microbiol)
- "Compared with the wild-type strain, the ampH-knockout strain exhibited significantly increased MICs for carbenicillin, piperacillin, cefalotin, cefoxitin, cefuroxime, cefotaxime, ceftazidime, cefepime, aztreonam, and ertapenem by at least 2-, 4-, 8-, 4-, 4-, 4-, 4-, 4-, 4-, and 2-fold, respectively. Under ceftazidime stress, P. diazotrophicus reduced aldB expression to increase its tolerance to the antibiotic. The discovery of the mechanism by which AcoR regulates aldB expression provides preliminary evidence for subsequent research on drug resistance mechanisms."
IO biomarker • Journal • Infectious Disease • ACACA • PD-1
November 24, 2025
Effective therapeutic strategies against Pseudomonas aeruginosa and Burkholderia Cepacia complex infections.
(PubMed, Sci Rep)
- "Significant differences in susceptibility were observed with P. aeruginosa isolates having more susceptibility to colistin and ceftazidime, while Burkholderia isolates were more susceptible to cotrimoxazole and minocycline. Both P. aeruginosa and Burkholderia isolates tested were more susceptible to N-Acetyl-L-Cysteine (NALC) plus meropenem or levofloxacin, followed by gentamicin plus piperacillin/tazobactam. Synergistic effect of NALC plus meropenem or levofloxacin may help in the eradication of both pathogens to overcome the diagnostic challenges posed by the possible misidentification using conventional identification methods."
Journal • Infectious Disease
November 27, 2025
A clinically relevant reinterpretation of disk approximation testing for inducible AmpC in Pseudomonas aeruginosa.
(PubMed, Rev Esp Quimioter)
- "Our reinterpretation criterion for disk approximation test turns a phenotypic assay into a clinically relevant diagnostic tool to avoid errors in ceftazidime susceptibility reports. Moreover, this interpretation is readily applicable in routine microbiology laboratories, and has the potential to be directly useful for antimicrobial stewardship efforts."
Journal
November 27, 2025
Phenyllactic Acid as a Marker of Antibiotic-Induced Metabolic Activity of Nosocomial Strains of Klebsiella pneumoniae In Vitro Experiment.
(PubMed, Microorganisms)
- "Doxycycline, nitrofurantoin, rifampicin, and tigecycline significantly suppressed metabolic activity, confirmed by decreased PhLA levels. Conversely, meropenem, cephalosporins (ceftriaxone, cefepime, cefotaxime, and ceftazidime), ciprofloxacin, and amikacin stimulated PhLA production, suggesting that bacterial metabolic activity was maintained despite the presence of antibiotics. PhLA is a promising biomarker for quantifying K. pneumoniae's metabolic response to antibiotics. This potentially introduces a novel approach for future investigations into resistance mechanisms and has the potential to increase the effectiveness of therapies for multidrug-resistant K. pneumoniae infections by providing an additional analytical tool to traditional susceptibility testing methodologies."
Journal • Preclinical • Infectious Disease • Pneumonia • Septic Shock
1 to 25
Of
3726
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150